Clinical Data AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis BioSpaceUCB's Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie's Skyrizi in a Phase 3 head-to-head study of psoriatic arthritis.Immunology & InflammationRead full story pharminent May 20, 2026 (Last updated: May 21, 2026) BioSpace UCB’s Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie’s Skyrizi in a Phase 3 head-to-head study of psoriatic arthritis. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: GHO, CBC merge to create largest healthcare investment firmNext: Parabilis follows hefty Regeneron deal with IPO push Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
